Strides Pharma Science LtdNSE: STAR

Strides Pharma Science Limited has informed the Exchange regarding a press release dated October 29, 2026, titled "Strides Delivers Strong Performance with Q2FY27 Revenue at ₹14,297m, Grew 17% YoYEx-US Markets Up 31% YoY; EBITDA Up 8% YoY to ₹2,509m, Crossing ₹2,500m in a Quarter for the First Time".

· Issued by Strides Pharma Science Ltd via NSE India

Filed with NSE · ISIN INE939A01011 ·

On 6ix: 6ix.com/news/strides-pharma-science-limited-has-informed-the-exchange-regarding-a-press-release-dated-october-29-2026-titled-strides-delivers-strong-performance-with-q2fy27-revenue-at-and837714297m-grew-17percent-yoyex-us-markets-up-31percent-yoy-ebitda-up-8percent-yoy-to-and83772509m-crossing-and83772500m-in-a-quarter-for-the-first-time

Strides Pharma Science Limited

View Attachment

6ix is reading this filing.

View original source (NSE India)Strides Pharma Science Ltd on 6ix

In the deck

Earlier from Strides Pharma Science

All Strides Pharma Science news releases